In this study, we found that the mean proportion of CD34+ CD38low/−LSCs was statistically significantly lower in patient with acute leukemia in CR compared to patients with non-CR and this agreed with Hwang and colleague, who had demonstrated in a group of 54 AML patients, that the proportion of CD34+ CD38low/−cells at diagnosis was significantly lower in patients achieving CR compared to patients who did not achieve CR [19]. This evidence concerns the gene CD34 and acute leukemia.